Automate Your Wheel Strategy on DXCM
With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXCM
- Rev/Share 10.9686
- Book/Share 6.5624
- PB 11.4037
- Debt/Equity 1.0024
- CurrentRatio 1.5203
- ROIC 0.0954
- MktCap 29346919425.0
- FreeCF/Share 1.4558
- PFCF 51.4137
- PE 51.3435
- Debt/Assets 0.352
- DivYield 0
- ROE 0.2562
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DXCM | Argus | -- | Buy | -- | $100 | Aug. 21, 2025 |
| Initiation | DXCM | Truist | -- | Buy | -- | $102 | June 16, 2025 |
| Initiation | DXCM | Goldman | -- | Buy | -- | $104 | May 30, 2025 |
| Initiation | DXCM | Mizuho | -- | Outperform | -- | $85 | April 10, 2025 |
| Upgrade | DXCM | Redburn Atlantic | Neutral | Buy | $85 | $115 | Feb. 3, 2025 |
| Upgrade | DXCM | Robert W. Baird | Neutral | Outperform | $86 | $104 | Jan. 16, 2025 |
News
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
Published: April 10, 2025 by: Barrons
Sentiment: Positive
DexCom says its G7 15 Day system will land on the market in the second half of 2025.
Read More
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear's previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unpre.
Read More
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Read More
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried
Published: March 10, 2025 by: Investors Business Daily
Sentiment: Negative
Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S. The post Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried appeared first on Investor's Business Daily.
Read More
DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
DexCom, Inc. (NASDAQ:DXCM ) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of Investor Relations Conference Call Participants Jayson Bedford - Raymond James Jayson Bedford Good morning. Welcome to the 46th Annual Raymond James Institutional Investors Conference.
Read More
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Published: February 26, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns.
Read More
Quality Key in Volatile Market, NFLX & DXCM Value Plays
Published: February 21, 2025 by: Schwab Network
Sentiment: Neutral
Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster strength but suggest investors bring an "umbrella' to protect their portfolios.
Read More
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Read More
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
Published: February 14, 2025 by: Benzinga
Sentiment: Positive
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
Read More
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Read More
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris …
Read More
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
Published: February 13, 2025 by: Reuters
Sentiment: Positive
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Read More
About DexCom, Inc. (DXCM)
- IPO Date 2005-04-14
- Website https://www.dexcom.com
- Industry Medical - Devices
- CEO Kevin Ronald Sayer
- Employees 10200